SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 25.00K shares.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 39.08K shares.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 0.00 shares.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 3.78K shares, a 113.08% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.77K shares, a 98.03% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 90.26K shares, a 622.11% increase from fiscal 2021.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 12.50K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 25.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | 39.08K shares 10-Q · filed 2026-05-12 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 3.78K shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -2.45K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.05K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 3.78K shares 10-Q · filed 2024-05-20 | 2.05K shares derived: sum of 4 quarters · filed 2024-05-20 |
| 2023-12-31 | -6.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 1.77K shares 10-K · filed 2024-03-29 |
| 2023-09-30 | 4.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 8.00K shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | 3.50K shares derived: sum of 4 quarters · filed 2023-08-21 |
| 2023-03-31 | 3.50K shares 10-Q · filed 2023-05-15 | 79.26K shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-14 | 90.26K shares 10-K · filed 2023-04-14 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2022-06-30 | 75.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | |
| 2022-03-31 | 14.50K shares 10-Q · filed 2022-05-12 | |
| 2021-12-31 | 12.50K shares 10-K/A · filed 2023-04-28 | |
| 2020-12-31 | 0.00 shares 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |